Tacquard C, Collange O, Gomis P, Malinovsky J-M, Petitpain N, Demoly P, Nicoll S, Mertes P M
Department of Anaesthesiology and Intensive Care, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
Department of Anaesthesiology and Intensive Care, Hôpital Maison Blanche, CHU de Reims, Reims, France.
Acta Anaesthesiol Scand. 2017 Mar;61(3):290-299. doi: 10.1111/aas.12855.
Immediate hypersensitivity reactions during anaesthesia are rare but potentially life-threatening. The epidemiology changes with time and evolving professional practice, and hence needs to be monitored. Our objective was to follow this epidemiology.
This was a retrospective, observational study in French hospital clinics, conducted by GERAP members (Groupe d'Étude des Réactions Anaphylactoïdes Périopératoires). Consecutive patients seen in allergo-anaesthesia outpatient clinics, who had experienced a hypersensitivity reaction during anaesthesia between 1 January 2011 and 31 December 2012, were included. Demographic data, allergy history, drugs received before the reaction, symptoms of the reaction, results of blood samples (histamine, tryptase, IgE-specific assays), and results of the allergy assessment were recorded.
The most common causes of allergic reactions were (Neuromuscular Blocking Agents) NMBAs (N = 302; 60.6%), antibiotics (N = 91, 18.2%, Cephalosporin N = 49, 10%) and dyes (N = 27; 5.4%). Latex as an allergic agent was involved in 26 cases (5.2%), hypnotics in 11 cases (2.2%) and opioids in seven cases (1.4%). Of the NMBAs, Rocuronium had the highest proportion of reactions (13.8 reactions/100,000 vials sold) followed by Suxamethonium (13.3/100,000 vials sold). Cisatracurium had the lowest proportion of reactions (0.4/100,000 vials sold). Patients were sensitized to two or more NMBAs in 48.9% of cases and without testing, cross-sensitivity cannot be predicted.
When compared with the previous GERAP studies, NMBAs are still the most frequently triggering allergens, with marked differences between individual NMBAs, but they are now followed by antibiotics (of which greater than 50% were cephalosporins) and dyes. Anaesthetists must be aware of the differences between drugs and of the pattern of emerging allergens. For the future of safe anaesthesia, allergy assessment is essential.
麻醉期间的速发型超敏反应虽罕见,但可能危及生命。其流行病学随时间及专业实践的发展而变化,因此需要进行监测。我们的目标是追踪这一流行病学情况。
这是一项在法国医院诊所开展的回顾性观察研究,由GERAP成员(围手术期过敏反应研究小组)进行。纳入2011年1月1日至2012年12月31日期间在过敏麻醉门诊就诊、麻醉期间发生过敏反应的连续患者。记录人口统计学数据、过敏史、反应前使用的药物、反应症状、血样结果(组胺、类胰蛋白酶、特异性IgE检测)以及过敏评估结果。
过敏反应最常见的原因是神经肌肉阻滞剂(NMBAs)(N = 302;60.6%)、抗生素(N = 91,18.2%,头孢菌素N = 49,10%)和染料(N = 27;5.4%)。作为变应原的乳胶涉及26例(5.2%),催眠药涉及11例(2.2%),阿片类药物涉及7例(1.4%)。在NMBAs中,罗库溴铵的反应比例最高(每售出100,000瓶有13.8次反应),其次是琥珀胆碱(每售出100,000瓶有13.3次反应)。顺式阿曲库铵的反应比例最低(每售出100,000瓶有0.4次反应)。48.9%的病例中患者对两种或更多种NMBAs致敏,且未经检测无法预测交叉敏感性。
与之前的GERAP研究相比,NMBAs仍是最常引发过敏的变应原,各NMBAs之间存在显著差异,但现在其次是抗生素(其中超过50%为头孢菌素)和染料。麻醉医生必须了解药物之间的差异以及新出现变应原的模式。为了安全麻醉的未来,过敏评估至关重要。